Market Spotlight: Glaucoma
Market Spotlight: Glaucoma
This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Glaucoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, patent information, recent events and analyst opinion, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
- Datamonitor Healthcare estimates that in 2017, there were 95.5 million prevalent cases of glaucoma in adults aged 40 years and older worldwide, and forecasts that number to increase to 113.4 million prevalent cases by 2026.
- Africa is estimated to have the highest disease prevalence (4.79%), while Europe and Oceania have the lowest prevalence (2.93% and 2.97%, respectively).
- The majority of approved drugs in the glaucoma space target beta adrenergic receptors or the prostaglandin F receptor. Zioptan and Neptazane (generic) are the only marketed drugs for glaucoma administered via the intraocular/subretinal/subconjunctival, and oral routes, respectively, with the remainder being topical formulations.
- The majority of industry-sponsored drugs in active clinical development for glaucoma are in Phase II, with only one drug in the NDA/BLA phase.
- While a small number of mid-to-late-stage drugs in the glaucoma space are exploring new targets, the established target prostaglandin F receptor continues to lead clinical development. The largest number of drugs in mid-to-late-stage development for glaucoma are administered via the intraocular/subretinal/subconjunctival route.
- High-impact upcoming events for drugs in the glaucoma space comprise expected CHMP supplemental filing results for Ganfort, topline Phase II trial results for Nyxol, and an expected PDUFA date for Bimatoprost Sustained Release.
- The overall likelihood of approval of a Phase I glaucoma/ocular hypertension (ophthalmology) asset is 4%, and the average probability a drug advances from Phase III is 61.5%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.
- There have been 25 licensing and asset acquisition deals involving glaucoma drugs during 2014–19. The largest deal was in 2014, when Merck & Co sold Asian rights for five of its glaucoma drugs to Santen for $600m.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for glaucoma have been in the late phases of development, with 59% of trials in Phase III–IV, and 41% in Phase I–II.
- The US has a substantial lead in the number of glaucoma clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the glaucoma space is dominated by completed trials. Novartis has the highest number of completed clinical trials for glaucoma, with 157 trials.
- Novartis leads industry sponsors with by far the highest overall number of clinical trials for glaucoma, followed by Allergan.
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
10 Eye drops
10 Oral medications
14 MARKETED DRUGS
20 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 NCX 470 for Glaucoma (October 2, 2019)
28 Multiple Drugs/Devices for Glaucoma (June 25, 2019)
29 OTX-TP for Glaucoma (May 20, 2019)
30 Hydrus Microstent for Glaucoma (April 23, 2019)
32 CyPass Micro-Stent for Glaucoma (April 9, 2019)
33 Bimatoprost Sustained Release for Glaucoma (January 7, 2019)
35 KEY UPCOMING EVENTS
36 KEY REGULATORY EVENTS
36 FDA Greenlights Rocklatan Following Superiority Over Rhopressa
37 PROBABILITY OF SUCCESS
38 LICENSING AND ASSET ACQUISITION DEALS
38 Novartis, Mundipharma In Taiwan Ophthalmology Deal
38 Glaukos Gets US Distribution Rights To Santen’s MicroShunt
39 Ocumension Gets Certain Asian Rights To NicOx’s Glaucoma Compound
40 PARENT PATENTS
41 REVENUE OPPORTUNITY
43 CLINICAL TRIAL LANDSCAPE
44 Sponsors by status
45 Sponsors by phase
46 Recent events
47 Prescription information
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of glaucoma, 2017–26
20 Figure 2: Overview of pipeline drugs for glaucoma in the US
20 Figure 3: Pipeline drugs for glaucoma, by company
21 Figure 4: Pipeline drugs for glaucoma, by drug type
21 Figure 5: Pipeline drugs for glaucoma, by classification
28 Figure 6: NCX 470 for Glaucoma (October 2, 2019): Phase II – vs. Latanoprost 0.005% (U.S.)
30 Figure 7: OTX-TP for Glaucoma (May 20, 2019): Phase III – vs. Placebo (First)
32 Figure 8: Hydrus Microstent for Glaucoma (April 23, 2019): COMPARE (US)
34 Figure 9: Bimatoprost Sustained Release for Glaucoma (January 7, 2019): Phase III – 092
35 Figure 10: Key upcoming events in glaucoma
37 Figure 11: Probability of success in the glaucoma pipeline
38 Figure 12: Licensing and asset acquisition deals in glaucoma, 2014–19
40 Figure 13: Parent patents in glaucoma
43 Figure 14: Clinical trials in glaucoma
43 Figure 15: Top 10 drugs for clinical trials in glaucoma
44 Figure 16: Top 10 companies for clinical trials in glaucoma
44 Figure 17: Trial locations in glaucoma
45 Figure 18: Glaucoma trials status
LIST OF TABLES
46 Figure 19: Glaucoma trials sponsors, by phase
11 Table 1: Prevalent cases of glaucoma, 2017–26
13 Table 2: Prevalence proportions in glaucoma, 2017–26
15 Table 3: Marketed drugs for glaucoma
22 Table 4: Pipeline drugs for glaucoma in the US
27 Table 5: NCX 470 for Glaucoma (October 2, 2019)
28 Table 6: Multiple Drugs/Devices for Glaucoma (June 25, 2019)
29 Table 7: OTX-TP for Glaucoma (May 20, 2019)
31 Table 8: Hydrus Microstent for Glaucoma (April 23, 2019)
32 Table 9: CyPass Micro-Stent for Glaucoma (April 9, 2019)
34 Table 10: Bimatoprost Sustained Release for Glaucoma (January 7, 2019)
41 Table 11: Historical global sales, by drug ($m), 2014–18
42 Table 12: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.